A Scoring System to Optimize Pioglitazone Therapy after Stroke Based on Fracture Risk

BACKGROUND AND PURPOSE: The insulin sensitizer, pioglitazone, reduces cardiovascular risk in patients after an ischemic stroke or TIA but increases bone fracture risk. We conducted a secondary analysis of the Insulin Resistance Intervention after Stroke (IRIS) trial to assess the effect of pre-treat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Stroke
Autors principals: Viscoli, Catherine M., Kent, David M., Conwit, Robin, Dearborn, Jennifer L., Furie, Karen L., Gorman, Mark, Guarino, Peter D., Inzucchi, Silvio E., Stuart, Amber, Young, Lawrence H., Kernan, Walter N.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6557695/
https://ncbi.nlm.nih.gov/pubmed/30580725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.118.022745
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars